This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignees: Imuthes Limited, Institute of Organic Chemistry and Biochemistry, Vyzkumny Ustav Veterinarniho Lekarstvi, V.v.i.. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 50 
1 out of 3 Years Active: 2014
Title: Karsten Hipler: Innovator in Immunomodulation
Introduction
Karsten Hipler is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of immunology through his innovative work on glycopeptide compounds. His research focuses on developing compounds that can enhance the efficacy of vaccines.
Latest Patents
Karsten Hipler holds a patent for "Normuramyl glycopeptide compounds." This invention provides a compound that can act as an adjuvant, featuring specific structural formulas. The compounds can be incorporated into liposomes and micelles, functioning as immunomodulators alongside desired antigens or DNA encoding the antigens in vaccines. He has 1 patent to his name.
Career Highlights
Throughout his career, Karsten Hipler has worked with various organizations, including Imuthes Limited and the Veterinary Research Institute. His expertise in immunology and vaccine development has positioned him as a valuable contributor to the scientific community.
Collaborations
Karsten has collaborated with notable individuals in his field, including Jaroslav Turanek and Andrew David Miller. These partnerships have furthered his research and innovation in immunomodulation.
Conclusion
Karsten Hipler's work in developing normuramyl glycopeptide compounds showcases his commitment to advancing vaccine technology. His contributions are significant in the ongoing efforts to improve immunological responses in medical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile